Subscribe
Pet Food & CPG
10 min read

Dylan Munro | Co-Founder & COO, Spot & Tango

Spot & Tango grew from 12 boxes a week to 200 million meals served and an estimated $130M in revenue — 95% subscription, zero retail. Co-founder and COO Dylan Munro on why the company spent tens of millions building its own factory, how vertical integration cut UnKibble's cost nearly in half, and why frugality still governs a business investing at scale.

Written by
Roy Ben-Tzvi
Published on
November 11, 2026
Dylan Munro, Co-Founder and COO of Spot & Tango

Before co-founding Spot & Tango, Dylan Munro was studying high-growth consumer brands at McKinsey, analyzing what separated great businesses from merely good ones. That experience gave him a front-row seat to what makes a company durable, and helped shape the blueprint for what Spot & Tango would become.

Eight years later, Spot & Tango is a profitable business generating an estimated $120–130 million in annual revenue, growing 60–70% year-over-year, with roughly 95% of sales coming through subscriptions. The company has invested tens of millions of dollars into building its own manufacturing, recently committing another $20 million to expand its Allentown facility and double production capacity, all while continuing to avoid traditional retail.

In this conversation, Munro explains why most pet food brands are really marketing companies, what it took to build manufacturing from scratch, how Spot & Tango turned a customer complaint into its flagship product, why frugality remains a core operating principle even after investing tens of millions, and how AI is beginning to reshape supply chain operations.

You were at McKinsey studying DTC brands before you co-founded one. Did that work basically show you the blueprint for what you wanted to build?

While at McKinsey, I was lucky to work both directly with DTC brands and also with investment firms who were deciding whether to invest in or acquire DTC brands. This gave me multiple perspectives into what makes a great ecommerce company across culture, execution, operations, marketing, and financial performance.

So, when I left McKinsey to co-found Spot & Tango, I knew what “good” looked like, and I’ve strived to build Spot & Tango into that kind of business. The key is to first build a product that is truly differentiated and that people love, and then build on that product-market fit to quickly prove that the unit economics — customer acquisition cost compared to the lifetime value of a customer — can work at scale.

Ultimately, by following these principles, we have been able to build a scaled, profitable business growing 60-70% year-over-year, and have made hundreds of thousands of dogs happier and healthier along the way.

More on Spot & Tango from The Underbite

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

Pro
Keep Reading

Other Interviews

More conversations with founders, operators, and investors building the future of pet care.

Learn more
Deven Vespi | Advisor, DRV Advisory
Pet Health & Wellness
13 min read

Deven Vespi | Advisor, DRV Advisory

Clinically proven has no shared definition in pet, yet it now shapes deals as much as labels. Deven Vespi learned the trade in FDA-regulated animal health, and she explains how to check a study before you trust it or build a deal on it. She covers sample sizes, dosing gaps, why brands get blindsided by their own research, and how long published data stays an edge.

Learn more
Learn more
Meet the Founders: 3 Startups Shaping the Future of Pet Health
Pet Health & Wellness
10 min read

Meet the Founders: 3 Startups Shaping the Future of Pet Health

Pawsible Ventures took seven of more than 130 applicants into its second cohort. Three of them work very different corners of pet health. Nicole Shlomof and Gila Leibovitch of Pawp Water sell functional water to owners who already fill the bowl, Andria Beal of EpiPaws turned dolphin epigenetics research into biological-age tests for dogs and cats, and Elliot Greenwood of ChckVet sells software to vet practices that resist new tech.

Learn more
Learn more
Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics
Pet Health & Wellness
17 min read

Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics

Elizabeth Iorns lost her French Bulldog to a brain tumor that a published canine study suggested could be treated, but no company had taken the drug forward for dogs. Now she and Science Exchange co-founder Dan Knox license the companion animal rights to human drugs at Familiar Therapeutics: 13 programs and $5 million raised in five months, plus a pitch to pharma that pet trials validate targets faster than phase two.

Learn more
View all interviews